These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
837 related articles for article (PubMed ID: 28259002)
1. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells. Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002 [TBL] [Abstract][Full Text] [Related]
2. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells. Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098 [TBL] [Abstract][Full Text] [Related]
3. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508 [TBL] [Abstract][Full Text] [Related]
4. DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice. Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zheng YP; Hong T; He JS Immunol Lett; 2016 Nov; 179():95-101. PubMed ID: 27688078 [TBL] [Abstract][Full Text] [Related]
5. Enhanced effects of DNA vaccine against botulinum neurotoxin serotype A by targeting antigen to dendritic cells. Chen BY; Zhou G; Li QL; Lu JS; Shi DY; Pang XB; Zhou XW; Yu YZ; Huang PT Immunol Lett; 2017 Oct; 190():118-124. PubMed ID: 28802641 [TBL] [Abstract][Full Text] [Related]
7. Protection against respiratory syncytial virus infection by DNA immunization. Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950 [TBL] [Abstract][Full Text] [Related]
8. Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus. Hu B; Jiang J; Zhan J; Li G; Jiang Y; Guan X; Chen Y; Fang Z Virol J; 2014 Aug; 11():142. PubMed ID: 25107552 [TBL] [Abstract][Full Text] [Related]
9. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. Spender LC; Hussell T; Openshaw PJ J Gen Virol; 1998 Jul; 79 ( Pt 7)():1751-8. PubMed ID: 9680139 [TBL] [Abstract][Full Text] [Related]
10. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4 Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB Front Immunol; 2019; 10():59. PubMed ID: 30761131 [TBL] [Abstract][Full Text] [Related]
11. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001 [TBL] [Abstract][Full Text] [Related]
12. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271 [TBL] [Abstract][Full Text] [Related]
14. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3. Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204 [TBL] [Abstract][Full Text] [Related]
15. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice. Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682 [TBL] [Abstract][Full Text] [Related]
16. A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus. Garg R; Theaker M; Martinez EC; van Drunen Littel-van den Hurk S Virology; 2016 Dec; 499():288-297. PubMed ID: 27721128 [TBL] [Abstract][Full Text] [Related]
17. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198 [TBL] [Abstract][Full Text] [Related]
18. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590 [TBL] [Abstract][Full Text] [Related]
20. Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins. Lee YT; Ko EJ; Kim KH; Hwang HS; Lee Y; Kwon YM; Kim MC; Lee YN; Jung YJ; Kang SM J Biomed Nanotechnol; 2017 Jan; 13(1):84-98. PubMed ID: 29302248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]